Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller

American Journal of Gastroenterology

Volumn 109, Issue 8, 2014, Pages 1234-1240

  Kim, Jong Woo ^a   Kim, Jin Hyoung ^a   Sung, Kyu Bo ^a   Ko, Heung Kyu ^a   Shin, Ji Hoon ^a   Kim, Pyo Nyun ^a   Choi, Hyun Kyung ^a   Ko, Gi Young ^a   Yoon, Hyun Ki ^a   Chun, Seng Yong ^a   Gwon, Dong Il ^a  

^a University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; ETHIODIZED OIL; FEMALE; GELATIN SPONGE, ABSORBABLE; HEMOSTATICS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84905578765     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.152     Document Type: Article

References (43)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340 : 745-50.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 : 1907-17.
3. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 : S5-S16.
4. Santi V, Trevisani F, Gramenzi A et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53 : 291-7.
5. Kudo M. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25 : 439-52.
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35 : 421-30.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42 : 1208-36.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 : 1020-2.
9. Roayaie S, Obeidat K, Sposito C et al. Resection of hepatocellular cancer = 2 cm: results from two Western centers. Hepatology 2013; 57 : 1426-35.
10. Midorikawa Y, Takayama T, Shimada K et al. Marginal survival benefi t in the treatment of early hepatocellular carcinoma. J Hepatol 2013; 58 : 306-11.
11. Peng ZW, Lin XJ, Zhang YJ et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology 2012; 262 : 1022-33.
12. Cucchetti A, Piscaglia F, Cescon M et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59 : 300-7.
13. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 : 693-9.
14. Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243 : 321-8.
15. Choi D, Lim HK, Rhim H et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a fi rst-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007; 17 : 684-92.
16. Chan AC, Poon RT, Ng KK et al. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefi t of early detection by screening. Ann Surg 2008; 247 : 666-73.
17. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47 : 82-9.
18. Komorizono Y, Oketani M, Sako K et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003; 97 : 1253-62.
19. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 : 1164-71.
20. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 : 1734-9.
21. Kang JW, Kim JH, Ko GY et al. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012; 53 : 545-50.
22. Lencioni R, Llovet JM. Modifi ed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 : 52-60.
23. Goldberg SN, Grassi CJ, Cardella JF et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2009; 20 : S377-90.
24. Leoni CJ, Potter JE, Rosen MP et al. Classifying complications of interventional procedures: a survey of practicing radiologists. J Vasc Interv Radiol 2001; 12 : 55-9.
25. Hsu CY, Huang YH, Chiou YY et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl 2011; 17 : 556-66.
26. Liem MS, Poon RT, Lo CM et al. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005; 11 : 4465-71.
27. Yang MJ, An SY, Moon EJ et al. Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. Korean J Hepatol 2009; 15 : 474-85.
28. Memon K, Kulik L, Lewandowski RJ et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011; 141 : 526-35.
29. Takahashi S, Kudo M, Chung H et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; 72 (Suppl 1) : 98-103.
30. Makuuchi M. Remodeling the surgical approach to hepatocellular carcinoma. Hepatogastroenterology 2002; 49 : 36-40.
31. Nakazawa T, Kokubu S, Shibuya A et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188 : 480-8.
32. Miyayama S, Mitsui T, Zen Y et al. Histopathological fi ndings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009; 39 : 374-81.
33. Eur J Radiol 2012; 81 : e189-93.
34. Ekelund L, Lin G, Jeppsson B. Blood supply of experimental liver tumors after intraarterial embolization with gelfoam powder and absolute ethanol. Cardiovasc Intervent Radiol 1984; 7 : 234-9.
35. Kuroda C, Sakurai M, Monden M et al. Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma. A study in resected cases. Cancer 1991; 67 : 81-6.
36. Miyayama S, Matsui O, Yamashiro M et al. Iodized oil accumulation in the hypovascular tumor portion of early-stage hepatocellular carcinoma after ultraselective transcatheter arterial chemoembolization. Hepatol Int 2007; 1 : 451-9.
37. Yuki K, Hirohashi S, Sakamoto M et al. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990; 66 : 2174-9.
38. Terayama N, Matsui O, Gabata T et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol 2002; 24 : 383-7.
39. Zhou Z, Lei J, Li B et al. Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule 2 cm): a single-center study. Eur J Gastroenterol Hepatol, 2014; 26: 339-44.
40. Wang JH, Wang CC, Hung CH et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2012; 56 : 412-8.
41. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 2008; 14 : 117-22.
42. Shibata T, Isoda H, Hirokawa Y et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009; 252 : 905-13.
43. Kim JW, Kim JH, Won HJ et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol 2012; 81 : e189-93.